Researchers from a group led by Professor Dr Jordi Surrallés at the Hospital de la Santa Creu i Sant Pau, Barcelona, the Universitat Autònoma de Barcelona and the CIBER of Rare Diseases (CIBERER) have identified of a new gene involved in Fanconi anemia, a rare genetic disease.
The authors of the study, published in the prestigious The Journal of Clinical Investigation, discovered specific mutations in the RFWD3 gene, related to DNA repair, which are involved in the development of this disorder. For this reason, researchers chose to use next-generation massive sequencing technology in the study.
Fanconi anemia is a hereditary disease caused by mutations in some of the genes related to DNA repair, a process which is essential for the maintenance of stem cells and the prevention of cancer. People affected by this serious disorder suffer from bone marrow failure, several congenital defects and have more chances of developing solid tumors and hematologic problems.
The authors of the research detected mutations in the RFWD3 gene in a child with Fanconi anaemia. They also confirmed the relation between the mutations and the disorder with functional studies in cell and animal models.
The research was coordinated by Detlev Schindler of the University of Würzburg, Germany. Participating were other researchers from the same university and from the University of Kyoto, as well as the group led by Surrallés, Chair Professor in Genetics at the Universitat Autònoma de Barcelona, head of the CIBERER research group and current director of the Genetics Unit at the Hospital de la Santa Creu i Sant Pau.
Until now, there was knowledge of 21 genes involved in Fanconi anemia. Three years ago, the research group coordinated by Dr Surrallés had already directed a study which gave way to the discovery of another of the genes causing this disorder, the FANCQ. The study was published in the American Journal of Human Genetics.
“The discovery of new genes is essential not only for genetic diagnosis and advice, but also for the development of new therapies. A good example is gene therapies in which we are already working on the clinical trials. The RFWD3 protein is of the few deficient proteins in patients with Fanconi anemia in which we can see a clear enzymatic activity (ubiquitin ligase), which opens the door to massive drug screenings. In this sense, my group has already worked on several screenings of thousands of therapeutic molecules with the aim of repositioning a drug for this disease”, Surrallés concluded.
Last editorial review: July 18, 2017
Featured Image: Blood Courtesy: © 2017 Fotolia. Used with permission. Photo 1.0: Professor Jordi Surrallés. Courtesy: © 2017. Hospital de la Santa Creu i Sant Pau. Used with permission.
Copyright © 2017 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine, Oncozine and The Onco’Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.